Literature DB >> 429566

Circulating immune complexes in Lyme arthritis. Detection by the 125I-C1q binding, C1q solid phase, and Raji cell assays.

J A Hardin, L C Walker, A C Steere, T C Trumble, K S Tung, R C Williams, S Ruddy, S E Malawista.   

Abstract

We have found immunoglobulin (Ig) G-containing material consistent with immune complexes in the sera of patients with Lyme arthritis. It was detected in 29 of 55 sera (55%) from 31 patients by at least one of three assays: (125)I-C1q binding, C1q solid phase, or Raji cell. The presence of reactive material correlated with clinical aspects of disease activity; it was found early in the illness, was most prominent in sera from the sickest patients, was infrequent during remissions, and often fluctuated in parallel with changes in clinical status. The results in the two C1q assays showed a strong positive correlation (P<0.001). They were each elevated in 45% of the sera and were usually concordant (85%). In contrast, the Raji cell assay was less frequently positive and often discordant with the C1q assays. In sucrose density gradients, putative circulating immune complexes sedimented near 19S; they, too, were detected best by the two assays based on C1q binding. An additional 7S component was found in some sera by the (125)I-C1q binding assay. Serum complement was often above the range of normal in patients with mild disease and normal in patients with severe disease but did not correlate significantly with levels of circulating immune complexes. IgM and IgG rheumatoid factors were not detectable. These findings support a role for immune complexes in the pathogenesis of Lyme arthritis. Their measurement, by either the (125)I-C1q binding assay or by the C1q solid phase assay, often provides a sensitive index of disease activity. Moreover, the complexes are likely sources of disease-related antigens for further study of this new disorder.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 429566      PMCID: PMC371975          DOI: 10.1172/JCI109324

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  25 in total

1.  Interactions of C-reactive protein with the first component of human complement.

Authors:  D R Claus; J Siegel; K Petras; A P Osmand; H Gewurz
Journal:  J Immunol       Date:  1977-07       Impact factor: 5.422

2.  Precise standardization of reagents for complement fixation.

Authors:  J F KENT; E H FIFE
Journal:  Am J Trop Med Hyg       Date:  1963-01       Impact factor: 2.345

3.  Preparation of iodine-131 labelled human growth hormone of high specific activity.

Authors:  W M HUNTER; F C GREENWOOD
Journal:  Nature       Date:  1962-05-05       Impact factor: 49.962

4.  The latex fixation test. I. Application to the serologic diagnosis of rheumatoid arthritis.

Authors:  C M PLOTZ; J M SINGER
Journal:  Am J Med       Date:  1956-12       Impact factor: 4.965

5.  Application of the solid phase C1q and Raji cell radioimmune assays for the detection of circulating immune complexes in glomerulonephritis.

Authors:  K S Tung; A J Woodroffe; T D Ahlin; R C Williams; C B Wilson
Journal:  J Clin Invest       Date:  1978-07       Impact factor: 14.808

6.  Erythema chronicum migrans and Lyme arthritis: epidemiologic evidence for a tick vector.

Authors:  A C Steere; T F Broderick; S E Malawista
Journal:  Am J Epidemiol       Date:  1978-10       Impact factor: 4.897

7.  Erythema chronicum migrans and lyme arthritis: field study of ticks.

Authors:  R C Wallis; S E Brown; K O Kloter; A J Main
Journal:  Am J Epidemiol       Date:  1978-10       Impact factor: 4.897

8.  Detection of immune complexes. The use of radioimmunoassays with Clq and monoclonal rheumatoid factor.

Authors:  A Gabriel; V Agnello
Journal:  J Clin Invest       Date:  1977-05       Impact factor: 14.808

9.  Immune complexes in congenital and natal cytomegalovirus infections of man.

Authors:  S Stagno; J E Volanakis; D W Reynolds; R Stroud; C A Alford
Journal:  J Clin Invest       Date:  1977-10       Impact factor: 14.808

10.  Circulating immune complexes in disseminated gonorrheal infection.

Authors:  L C Walker; T D Ahlin; K S Tung; R C Williams
Journal:  Ann Intern Med       Date:  1978-07       Impact factor: 25.391

View more
  19 in total

1.  Lyme borreliosis: host responses to Borrelia burgdorferi.

Authors:  A Szczepanski; J L Benach
Journal:  Microbiol Rev       Date:  1991-03

Review 2.  Lyme disease.

Authors:  D W Rahn; S E Malawista
Journal:  West J Med       Date:  1991-06

Review 3.  Pathogenesis of Lyme disease.

Authors:  S E Malawista
Journal:  Rheumatol Int       Date:  1989       Impact factor: 2.631

Review 4.  Immune complexes in human diseases: a review.

Authors:  A N Theofilopoulos; F J Dixon
Journal:  Am J Pathol       Date:  1980-08       Impact factor: 4.307

Review 5.  Laboratory aspects of Lyme borreliosis.

Authors:  A G Barbour
Journal:  Clin Microbiol Rev       Date:  1988-10       Impact factor: 26.132

6.  Antibodies of patients with Lyme disease to components of the Ixodes dammini spirochete.

Authors:  A G Barbour; W Burgdorfer; E Grunwaldt; A C Steere
Journal:  J Clin Invest       Date:  1983-08       Impact factor: 14.808

7.  Soluble immune complexes in patients with diabetes mellitus: detection and pathological significance.

Authors:  G Virella; H Wohltmann; J Sagel; M F Lopes-Virella; M Kilpatrick; C Phillips; J Colwell
Journal:  Diabetologia       Date:  1981-09       Impact factor: 10.122

8.  Use of serum immune complexes in a new test that accurately confirms early Lyme disease and active infection with Borrelia burgdorferi.

Authors:  M Brunner; L H Sigal
Journal:  J Clin Microbiol       Date:  2001-09       Impact factor: 5.948

9.  The immunoglobulin G subclass composition of immune complexes in cystic fibrosis. Implications for the pathogenesis of the Pseudomonas lung lesion.

Authors:  D B Hornick; R B Fick
Journal:  J Clin Invest       Date:  1990-10       Impact factor: 14.808

10.  Study of circulating immune complex size in systemic lupus erythematosus.

Authors:  K S Tung; R J DeHoratius; R C Williams
Journal:  Clin Exp Immunol       Date:  1981-03       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.